WHO updates its risk and treatment guidelines – continues to advise against Ivermectin and for Remdesivir

From here:

WHO updates guidelines on treatments for COVID-19

Literally on the bottom line of that update is this:

“The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.”

No doubt because IVM also blocks the progression of spike protein caused by C19 mRNA injections to vital organs.

Check out the Remdesivir guidelines.

“If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.”

V

“WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.”

Ok, so if you are at high risk of being hospitalized, Remdesivir can be used, but not if at moderate risk of being hospitalized.

So what about the new risk designations? Enter “Moderate risk”.

“The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease.”

Making these the risk categories:

·        High: People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.

·        Moderate: People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.

·        Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.

Which means that medics will have to be able to assess whether there is one in 17 chance or a one in 33 chance of hospitalization and they can do that assessment on the spot. In the US, those assessed to have a one in 17 chance get Remdesivir (and still get a huge bonus from the federal government?).

As a reminder, the WHO denies the existence of all evidence from studies of any kind involving Ivermectin.

Ivermectin for COVID-19: real-time analysis of all 230 studies (c19ivm.org)

Onwards!

Please subscribe or make a donation via ko-fi – any amount from 3 bucks upwards. Don’t worry and God Bless, if you can’t or don’t want to. Ko-fi donations here: https://ko-fi.com/peterhalligan - an annual subscription of 100 bucks is one third less than a $3 ko-fi donation a week!